UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency in the United Kingdom

Yong, Patrick F K; Coulter, Tanya; El-Shanwany, Tariq; Garcez, Tomaz; Hackett, Scott; Jain, Rashmi; Kiani-Alikhan, Sorena; ... Worth, Austen; + view all (2023) A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency in the United Kingdom. Journal of Allergy and Clinical Immunology: In Practice 10.1016/j.jaip.2023.04.035. (In press). Green open access

[thumbnail of Buckland_1-s2.0-S2213219823004762-main.pdf]
Preview
Text
Buckland_1-s2.0-S2213219823004762-main.pdf

Download (339kB) | Preview

Abstract

Background: Detailed demographic data on people with hereditary angioedema (HAE) and acquired C1 inhibitor deficiency in the United Kingdom are relatively limited. Better demographic data would be beneficial in planning service provision, identifying areas of improvement, and improving care./ Objective: To obtain more accurate data on the demographics of HAE and acquired C1 inhibitor deficiency in the United Kingdom, including treatment modalities and services available to patients./ Methods: A survey was distributed to all centers in the United Kingdom that look after patients with HAE and acquired C1 inhibitor deficiency to collect these data./ Results: The survey identified 1152 patients with HAE-1/2 (58% female and 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency. Data were provided by 37 centers across the United Kingdom. This gives a minimum prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency in the United Kingdom. A total of 45% of patients with HAE were on long-term prophylaxis (LTP) with the most used medication being danazol (55% of all patients on LTP). Eighty-two percent of patients with HAE had a home supply of acute treatment with C1 inhibitor or icatibant. A total of 45% of patients had a supply of icatibant and 56% had a supply of C1 inhibitor at home./ Conclusions: Data obtained from the survey provide useful information about the demographics and treatment modalities used in HAE and acquired C1 inhibitor deficiency in the United Kingdom. These data are useful for planning service provision and improving services for these patients.

Type: Article
Title: A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency in the United Kingdom
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jaip.2023.04.035
Publisher version: https://doi.org/10.1016/j.jaip.2023.04.03
Language: English
Additional information: © 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY 4.0 license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/
Keywords: Hereditary angioedema, acquired C1 inhibitor deficiency, androgens, demographics, epidemiology, icatibant, tranexamic acid
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/10171170
Downloads since deposit
32Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item